Business Context and Reporting Period
This Form 8-K Current Report was filed by Tonix Pharmaceuticals Holding Corp. (TNXP) on June 26, 2024. The report addresses a specific regulatory event regarding the company's listing status on the NASDAQ Capital Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on a corporate governance and listing compliance event.
Material Changes
The primary material event reported is the resolution of a listing deficiency:
- NASDAQ Compliance: The Company received notification from The NASDAQ Stock Market LLC that it has regained compliance with the minimum bid price requirement of $1.00 per share.
- Criteria Met: Compliance was achieved because the Company's shares maintained a closing bid price at or above $1.00 per share for a minimum of 10 consecutive business days.
- Status: The matter regarding the listing deficiency is now closed.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statements cautioning investors about risks related to product development, clinical trials, regulatory timelines, and market opportunities. The Company explicitly states it undertakes no obligation to update these statements. No specific financial guidance or operational outlook is provided in this document.
Investor Verification Checklist
- Verify the current trading price of TNXP to ensure continued compliance with the $1.00 minimum bid price requirement.
- Review the press release filed as Exhibit 99.01 for additional context on the listing status.
- Check subsequent filings for any new notices from NASDAQ regarding other listing standards (e.g., market value of listed securities or shareholder equity).